Gilead Sciences Reports Q3 2026 Earnings Results
Gilead's third-quarter presentation offers a snapshot of how a major US biopharma company is performing amid ongoing drug portfolio shifts, with results available through the company's official...
Gilead Sciences, Inc. (Nasdaq: GILD) released its third-quarter 2026 earnings call presentation on October 29, 2026, according to a transcript and presentation published by Seeking Alpha. The Foster City, California-based biopharmaceutical company is one of the largest US-listed drug makers by market capitalization, with its stock traded on the Nasdaq Stock Market.
The Seeking Alpha posting, attributed to SA Transcripts, confirms that Gilead held its Q3 2026 earnings call on October 29, 2026. The full financial figures from the presentation, including revenue, earnings per share, and product-level sales data, are contained in the company's official earnings materials. Gilead has not yet filed its Q3 2026 Form 10-Q with the Securities and Exchange Commission as of the date of this article; that filing will serve as the definitive source for audited quarterly figures.
Gilead's business is organized around several key therapeutic areas. Its HIV franchise, anchored by products including Biktarvy and Descovy, has historically been the company's largest revenue driver. According to Gilead's Q2 2026 Form 10-Q filed with the SEC, total product sales for the first six months of 2026 were reported in that filing, and investors were watching the Q3 call for updates on Biktarvy's market share trajectory as well as competition from generic entrants in older HIV product lines.
The oncology segment, which includes the cell therapy products Yescarta and Tecartus as well as the breast cancer drug Trodelvy, has been a closely watched growth area for the company. Gilead acquired Kite Pharma in 2017 for approximately $11.9 billion, according to SEC filings from that transaction, establishing its cell therapy presence. Analysts have monitored whether Trodelvy's sales trajectory in metastatic triple-negative breast cancer and urothelial cancer is accelerating, decelerating, or holding steady relative to prior quarters.
Gilead's hepatitis C franchise, once the company's dominant revenue source, has declined materially over the past decade as patient pools were treated and cured. The company has disclosed in prior annual reports filed with the SEC that HCV revenues have stabilized at lower levels compared to peak years in 2015 and 2016, when combined Harvoni and Sovaldi sales exceeded $19 billion annually.
The liver disease portfolio now includes lenacapavir, Gilead's long-acting HIV capsid inhibitor, which the company has been studying in HIV prevention trials. Data from the PURPOSE 1 and PURPOSE 2 trials, discussed in prior Gilead press releases, showed high efficacy for lenacapavir as pre-exposure prophylaxis. Whether regulatory submissions or approvals for lenacapavir in prevention indications were addressed in the Q3 2026 call is not yet confirmed in public records available at the time of this article's publication.
For context on Gilead's financial position, the company reported approximately $27.1 billion in total revenue for full-year 2025, according to its 2025 Form 10-K filed with the SEC. Net income and free cash flow figures for Q3 2026 will be confirmed upon release of the official earnings press release and subsequent 10-Q filing.
Gilead shares are held widely by institutional investors. As of the most recent 13F filings compiled by the SEC for the period ending June 30, 2026, major institutional holders included Vanguard Group, BlackRock, and State Street, consistent with their holdings across large-cap US equities. Individual shareholder impact depends on portfolio weighting and whether Q3 results came in above or below consensus analyst estimates, which are tracked by financial data providers such as FactSet and Bloomberg.
The Q3 2026 earnings call presentation is one of several major US corporate earnings releases on October 29, 2026. Investors and analysts typically compare quarterly results to the company's own prior guidance, to Wall Street consensus estimates, and to peer performance within the large-cap biopharma sector, which includes companies such as AbbVie, Bristol-Myers Squibb, and Amgen, all of which trade on US exchanges.
What remains unknown at this time is the precise revenue, operating income, and earnings-per-share figures from the Q3 2026 presentation, as well as any updated full-year 2026 guidance ranges Gilead may have issued. Those figures will be confirmed in the company's official SEC filings. Investors seeking the complete data set should consult Gilead's investor relations page and the SEC's EDGAR database once the 10-Q is filed.